Barclays and Evercore Stay Positive on Danaher (DHR) Despite Cutting Price Targets

Danaher Corporation (NYSE:DHR) is one of the 10 Unrivaled Stocks of the Next 5 Years. On April 14, Barclays reduced its price target on Danaher Corporation (NYSE:DHR) from $250 to $230 and maintained its Overweight rating on the stock.

The research firm adjusted price targets for the life sciences and diagnostic tools sector as part of its first-quarter preview. While Barclays remains positive about the overall setup for the sector, it noted that it is “not without risk.” The firm also highlighted that investor sentiment is at all-time low levels but it continues to support the “last-cut thesis (for the most part).”

Barclays and Evercore Stay Positive on Danaher (DHR) Despite Cutting Price Targets

Earlier, on April 6, Evercore ISI analyst Vijay Kumar also cut the firm’s price target on Danaher Corporation (NYSE:DHR) from $254 to $225 and maintained an Outperform rating on the stock.

Danaher Corporation (NYSE:DHR) was also added to Evercore ISI’s “Tactical Outperform” list as part of the firm’s Q1 preview for medical technology and life science tools companies.

Danaher Corporation (NYSE:DHR) is a leading global life sciences and diagnostics innovation company. The company is known for its professional, medical, research, and industrial products and services that help discover, develop, and deliver life-changing therapies.

While we acknowledge the risk and potential of DHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DHR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Performing AI Stocks to Buy and 10 Best Performing Blue Chip Stocks to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.